Journal article
The value of dual-energy X-ray absorptiometry (DEXA) scans in monitoring HIV patients on protease inhibitors
Nuclear Medicine Communications, Vol.20(4), pp.403-404
1999
Abstract
With the introduction of HIV protease inhibitors into clinical practice in late 1996, the management and outcome of patients with HIV infection have been greatly improved. However, subsequent findings have found that these drugs produce some complicating peripheral lipodystrophy, hyperlipidaemia and insulin resistance. As part of a protocol to monitor these side-effects, whole-body DEXA scans are performed to demonstrate and quantify fat mass in various areas of the body. Follow-up scans are performed every 4-5 months. How beneficial are these scans to the management of the patients or are they lost among the myriad of other procedures?
Details
- Title
- The value of dual-energy X-ray absorptiometry (DEXA) scans in monitoring HIV patients on protease inhibitors
- Authors/Creators
- G. Roff (Author/Creator)M. McCarthy (Author/Creator)C. Moore (Author/Creator)S. Mallal (Author/Creator)
- Publication Details
- Nuclear Medicine Communications, Vol.20(4), pp.403-404
- Publisher
- Lippincott Williams and Wilkins
- Identifiers
- 991005543383407891
- Murdoch Affiliation
- Murdoch University
- Language
- English
- Resource Type
- Journal article
Metrics
27 Record Views